Developer docs
API playgroundTry for free, no card

Search company profiles

Simnova

Full company profile

uuid0002jo3

Namestring
Simnova
Legal namestring
Shanghai Simnova Biotech Co., Ltd.
Websiteurl
simnovabio.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Simnova Biotherapeutics (Shanghai Simnova Biotech Co., Ltd. / 上海先博生物科技有限公司) is a clinical-stage biotech company developing engineered cell therapies for oncology and, secondarily, autoimmune indications. The company operates two proprietary technology platforms: a universal off-the-shelf CAR-NK platform — anchored on innovative CAR design for in-vivo persistence, mature donor screening, and an iPSC-NK backbone with multiple gene-editing capabilities — and a BiTE CAR-T platform that combines CARs with bispecific T-cell engagers in a single gene-modified T-cell product to address antigen escape and tumor heterogeneity in solid tumors. The disclosed pipeline comprises six wholly-owned clinical-stage programs (SNC103 targeting CD19; SNC112 targeting BCMA/GPRC5D for multiple myeloma; SNC113 and SNC115 in solid tumors; SNC109, a multi-target construct for glioblastoma; and SNC102, a BCMA BiTE CAR-T), plus two in-licensed in vivo panCAR programs from Orna Therapeutics (CD19/ORN-101 and a newly added BCMA program) for which Simnova holds Greater China rights.

The business model is pre-commercial: Simnova generates no product revenue today and intends to monetize through one-time product sales or licensing upon regulatory approval. GTM is the traditional clinical-stage biotech model — enterprise partnerships, direct engagement with clinical trial sites and KOLs, and conference-led scientific positioning — with planned distribution through specialty pharmacy and hospital channels post-approval. The company was founded in 2019 in Cambridge, Massachusetts, completed a GMP manufacturing facility in Shanghai in 2020, and was spun off from Simcere in 2021 to operate as an independent cell-therapy-focused entity. It is led by CEO Cao Zhuoxiao (M.D., Ph.D.), Clinical SVP Wen Limin (M.D., Ph.D.), and scientific advisors Dr. Wang Pin (USC) and Dr. Tamas Oravecz (CSO U.S. of Simcere), and is funded by a March 2024 ~$27.8M round led by Youshan Capital with Guochuang Qinzhi, Oriza Seed Capital, and PagodaTree Partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy, CAR-NK immunotherapy, CAR-T therapy, oncology biotech, allogeneic cell therapy
Industry1 code
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Cell Therapy Products
TypeOne Time License
Description

Pre-commercial stage. Simnova is developing CAR-NK and CAR-T cell therapies targeting hematologic malignancies and solid tumors. Revenue will be generated from product sales upon regulatory approval. The company has a rich R&D pipeline with programs in various clinical stages.

simnovabio.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Simnova (Shanghai Simnova Biotech Co., Ltd.) is a clinical-stage biotech company developing CAR-based cell therapies for cancer and autoimmune diseases. Its pipeline is built on two proprietary technology platforms: an allogeneic universal off-the-shelf CAR-NK platform (programs SNC103, SNC112, SNC113, SNC115) targeting hematologic malignancies and solid tumors, and a BiTE CAR-T platform (programs SNC109, SNC102) for glioblastoma and multiple myeloma. The company also in-licensed Orna Therapeutics' circular RNA-based in vivo cell therapies (ORN-101/BCMA panCAR) for development and commercialization in Greater China.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Simnova is a clinical-stage biotech company developing cell therapies for cancer treatment. The company's product portfolio centers on two proprietary technology platforms: an off-the-shelf universal CAR-NK platform (producing SNC103, SNC112, SNC113, and SNC115) and a BiTE CAR-T platform (producing SNC109 and SNC102). The CAR-NK platform features innovative CAR design, mature donor screening methods, and an iPSC-NK platform with gene editing capabilities. The BiTE CAR-T platform combines CARs with BiTEs into single gene-modified T-cell products to address solid tumor barriers. Simnova also collaborates with Orna Therapeutics on in vivo cell therapies using circular RNA technology, including ORN-101 (CD19-targeted) and BCMA-targeted programs, licensed for Greater China development.

Product and service2 records
1SNC103
CategoryCAR-NK cell therapy
Description

Allogeneic off-the-shelf CAR-NK cell therapy targeting CD19 for the treatment of B-cell malignancies. Developed on Simnova's universal off-the-shelf CAR-NK platform for oncology patients with hematologic cancers.

2SNC112
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-15
Description

Expanded strategic collaboration to include BCMA (B-cell maturation antigen) as a designated biological target for RNA-based therapeutics development. Simnova pursues research, development, and commercialization of in vivo panCAR cell therapies targeting BCMA in greater China. Orna retains rights for rest of world. Each party eligible for upfront payments, clinical development milestones, regulatory milestones, commercialization milestones, and royalties on approved products. Initial collaboration in January 2023 granted Simnova exclusive rights to develop and commercialize Orna's in vivo cell therapy products in Greater China, including ORN-101 (CD19 targeting isCAR project).

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Nkarta is a clinical-stage biotech developing off-the-shelf, allogeneic CAR-NK cell therapies for hematologic malignancies and solid tumors, directly comparable to Simnova's CAR-NK pipeline (SNC103, SNC112, SNC113, SNC115).

TypeDirect peer
Description

Fate develops iPSC-derived NK and T-cell therapies, including off-the-shelf CAR-NK products. Its iPSC platform and multiple gene-edited NK programs are closely analogous to Simnova's iPSC-NK and allogeneic CAR-NK strategy.

TypeDirect peer
Description

Adicet develops allogeneic gamma-delta CAR-T and CAR-NK cell therapies for hematologic malignancies and solid tumors, making it a direct off-the-shelf cell therapy peer to Simnova's CAR-NK and CAR-T programs.

TypeDirect peer
Description

Allogene is a pioneer in allogeneic, off-the-shelf CAR-T cell therapy with clinical assets in lymphoma and multiple myeloma — directly comparable to Simnova's allogeneic CAR-NK and BiTE CAR-T pipeline targeting similar indications.

TypeDirect peer
Description

Caribou develops allogeneic CAR-T cell therapies using CRISPR-based gene editing, with clinical programs in B-cell malignancies — overlapping with Simnova's CD19/BCMA allogeneic cell therapy pipeline.

TypeDirect peer
Description

Cellectis is a clinical-stage gene-editing company developing allogeneic CAR-T platforms (UCART), with multiple gene-edited programs in hematologic malignancies — directly comparable to Simnova's gene-edited iPSC-NK and CAR-T approach.

TypeDirect peer
Description

Century develops iPSC-derived, gene-edited allogeneic NK and T-cell therapies for hematologic and solid tumors. Its iPSC + multi-gene-editing platform closely parallels Simnova's iPSC-NK platform and gene-editing capabilities.

8Cytovia Therapeutics
TypeDirect peer
Description

Cytovia is developing iPSC-derived NK and CAR-NK cell therapies for solid tumors and hematologic cancers, with programs targeting similar indications (e.g., BCMA multiple myeloma) to Simnova's SNC112 and SNC102.

TypeBroad incumbent
Description

CRISPR Therapeutics is a commercial-stage gene-editing company with Casgevy (exa-cel) and an allogeneic CAR-T platform. It is a broader incumbent that competes with Simnova on gene-edited cell therapies, though at a larger scale and across more modalities.

TypeBroad incumbent
Description

2seventy bio is commercial-stage cell therapy company (Abecma, ide-cel for multiple myeloma). It competes with Simnova's BCMA programs (SNC102, SNC112) and provides a benchmark for CAR-T commercialization in BCMA multiple myeloma.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Simnova

Cell Therapysimnovabio.com

What Simnova does

Simnova Biotherapeutics (Shanghai Simnova Biotech Co., Ltd. / 上海先博生物科技有限公司) is a clinical-stage biotech company developing engineered cell therapies for oncology and, secondarily, autoimmune indications. The company operates two proprietary technology platforms: a universal off-the-shelf CAR-NK platform — anchored on innovative CAR design for in-vivo persistence, mature donor screening, and an iPSC-NK backbone with multiple gene-editing capabilities — and a BiTE CAR-T platform that combines CARs with bispecific T-cell engagers in a single gene-modified T-cell product to address antigen escape and tumor heterogeneity in solid tumors. The disclosed pipeline comprises six wholly-owned clinical-stage programs (SNC103 targeting CD19; SNC112 targeting BCMA/GPRC5D for multiple myeloma; SNC113 and SNC115 in solid tumors; SNC109, a multi-target construct for glioblastoma; and SNC102, a BCMA BiTE CAR-T), plus two in-licensed in vivo panCAR programs from Orna Therapeutics (CD19/ORN-101 and a newly added BCMA program) for which Simnova holds Greater China rights.

The business model is pre-commercial: Simnova generates no product revenue today and intends to monetize through one-time product sales or licensing upon regulatory approval. GTM is the traditional clinical-stage biotech model — enterprise partnerships, direct engagement with clinical trial sites and KOLs, and conference-led scientific positioning — with planned distribution through specialty pharmacy and hospital channels post-approval. The company was founded in 2019 in Cambridge, Massachusetts, completed a GMP manufacturing facility in Shanghai in 2020, and was spun off from Simcere in 2021 to operate as an independent cell-therapy-focused entity. It is led by CEO Cao Zhuoxiao (M.D., Ph.D.), Clinical SVP Wen Limin (M.D., Ph.D.), and scientific advisors Dr. Wang Pin (USC) and Dr. Tamas Oravecz (CSO U.S. of Simcere), and is funded by a March 2024 ~$27.8M round led by Youshan Capital with Guochuang Qinzhi, Oriza Seed Capital, and PagodaTree Partners.

Simnova firmographics

Firmographics
Name
Simnova
Legal name
Shanghai Simnova Biotech Co., Ltd.
Website
https://simnovabio.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Simnova industry classification

Industry
Product category
Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cell therapy
  • CAR-NK immunotherapy
  • CAR-T therapy
  • Oncology biotech
  • Allogeneic cell therapy

Where Simnova is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Simnova business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Cell Therapy Products: Pre-commercial stage. Simnova is developing CAR-NK and CAR-T cell therapies targeting hematologic malignancies and solid tumors. Revenue will be generated from product sales upon regulatory approval. The company has a rich R&D pipeline with programs in various clinical stages.

Go-to-market motion1 record

Marketing channels3 records

Simnova product offering

Product offering

Core offering

Simnova (Shanghai Simnova Biotech Co., Ltd.) is a clinical-stage biotech company developing CAR-based cell therapies for cancer and autoimmune diseases. Its pipeline is built on two proprietary technology platforms: an allogeneic universal off-the-shelf CAR-NK platform (programs SNC103, SNC112, SNC113, SNC115) targeting hematologic malignancies and solid tumors, and a BiTE CAR-T platform (programs SNC109, SNC102) for glioblastoma and multiple myeloma. The company also in-licensed Orna Therapeutics' circular RNA-based in vivo cell therapies (ORN-101/BCMA panCAR) for development and commercialization in Greater China.

Product overview

Simnova is a clinical-stage biotech company developing cell therapies for cancer treatment. The company's product portfolio centers on two proprietary technology platforms: an off-the-shelf universal CAR-NK platform (producing SNC103, SNC112, SNC113, and SNC115) and a BiTE CAR-T platform (producing SNC109 and SNC102). The CAR-NK platform features innovative CAR design, mature donor screening methods, and an iPSC-NK platform with gene editing capabilities. The BiTE CAR-T platform combines CARs with BiTEs into single gene-modified T-cell products to address solid tumor barriers. Simnova also collaborates with Orna Therapeutics on in vivo cell therapies using circular RNA technology, including ORN-101 (CD19-targeted) and BCMA-targeted programs, licensed for Greater China development.

Differentiator

Problem solved

Functional benefit

Products and services

  • SNC103 Allogeneic off-the-shelf CAR-NK cell therapy targeting CD19 for the treatment of B-cell malignancies. Developed on Simnova's universal off-the-shelf CAR-NK platform for oncology patients with hematologic cancers.
  • SNC112

Companies that use Simnova

Customer profile

Segments2 records

Ideal customer profiles1 record

Simnova technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Simnova partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Orna TherapeuticscoreStrategic or Co-development Partner · 15 January 2025Expanded strategic collaboration to include BCMA (B-cell maturation antigen) as a designated biological target for RNA-based therapeutics development. Simnova pursues research, development, and commercialization of in vivo panCAR cell therapies targeting BCMA in greater China. Orna retains rights for rest of world. Each party eligible for upfront payments, clinical development milestones, regulatory milestones, commercialization milestones, and royalties on approved products. Initial collaboration in January 2023 granted Simnova exclusive rights to develop and commercialize Orna's in vivo cell therapy products in Greater China, including ORN-101 (CD19 targeting isCAR project).

Scale indicators1 record

Recent moves7 records

Expansion highlights6 records

Simnova competitors and assessment

Company assessment

Direct peers

  • Nkarta Therapeutics: Nkarta is a clinical-stage biotech developing off-the-shelf, allogeneic CAR-NK cell therapies for hematologic malignancies and solid tumors, directly comparable to Simnova's CAR-NK pipeline (SNC103, SNC112, SNC113, SNC115).
  • Fate Therapeutics: Fate develops iPSC-derived NK and T-cell therapies, including off-the-shelf CAR-NK products. Its iPSC platform and multiple gene-edited NK programs are closely analogous to Simnova's iPSC-NK and allogeneic CAR-NK strategy.
  • Adicet Bio: Adicet develops allogeneic gamma-delta CAR-T and CAR-NK cell therapies for hematologic malignancies and solid tumors, making it a direct off-the-shelf cell therapy peer to Simnova's CAR-NK and CAR-T programs.
  • Allogene Therapeutics: Allogene is a pioneer in allogeneic, off-the-shelf CAR-T cell therapy with clinical assets in lymphoma and multiple myeloma — directly comparable to Simnova's allogeneic CAR-NK and BiTE CAR-T pipeline targeting similar indications.
  • Caribou Biosciences: Caribou develops allogeneic CAR-T cell therapies using CRISPR-based gene editing, with clinical programs in B-cell malignancies — overlapping with Simnova's CD19/BCMA allogeneic cell therapy pipeline.
  • Cellectis: Cellectis is a clinical-stage gene-editing company developing allogeneic CAR-T platforms (UCART), with multiple gene-edited programs in hematologic malignancies — directly comparable to Simnova's gene-edited iPSC-NK and CAR-T approach.
  • Century Therapeutics: Century develops iPSC-derived, gene-edited allogeneic NK and T-cell therapies for hematologic and solid tumors. Its iPSC + multi-gene-editing platform closely parallels Simnova's iPSC-NK platform and gene-editing capabilities.
  • Cytovia Therapeutics: Cytovia is developing iPSC-derived NK and CAR-NK cell therapies for solid tumors and hematologic cancers, with programs targeting similar indications (e.g., BCMA multiple myeloma) to Simnova's SNC112 and SNC102.

Broad incumbents

  • CRISPR Therapeutics: CRISPR Therapeutics is a commercial-stage gene-editing company with Casgevy (exa-cel) and an allogeneic CAR-T platform. It is a broader incumbent that competes with Simnova on gene-edited cell therapies, though at a larger scale and across more modalities.
  • 2seventy bio: 2seventy bio is commercial-stage cell therapy company (Abecma, ide-cel for multiple myeloma). It competes with Simnova's BCMA programs (SNC102, SNC112) and provides a benchmark for CAR-T commercialization in BCMA multiple myeloma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Simnova social profiles

Digital presence

Simnova financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Simnova leadership team

Management profile

Number of profiles

Profiles4 records

Simnova funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Simnova M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Simnova

What does Simnova do?

Simnova (Shanghai Simnova Biotech Co., Ltd.) is a clinical-stage biotech company developing CAR-based cell therapies for cancer and autoimmune diseases. Its pipeline is built on two proprietary technology platforms: an allogeneic universal off-the-shelf CAR-NK platform (programs SNC103, SNC112, SNC113, SNC115) targeting hematologic malignancies and solid tumors, and a BiTE CAR-T platform (programs SNC109, SNC102) for glioblastoma and multiple myeloma. The company also in-licensed Orna Therapeutics' circular RNA-based in vivo cell therapies (ORN-101/BCMA panCAR) for development and commercialization in Greater China.

Is Simnova a public or private company?

Simnova is a private company. It is classified as venture growth investor backed and is currently operating.

When was Simnova founded?

Simnova was founded in 2019. It employs 1 to 10 people.

Where is Simnova based?

Simnova is headquartered in Cambridge, United States, in the North America region.

How does Simnova make money?

One revenue line is on record: cell Therapy Products.

Who are Simnova's main competitors?

Direct peers on record are Nkarta Therapeutics, Fate Therapeutics, Adicet Bio, Allogene Therapeutics, Caribou Biosciences, Cellectis, Century Therapeutics and Cytovia Therapeutics. Broad incumbents are CRISPR Therapeutics and 2seventy bio.

Does Simnova have an API?

No public API is recorded for Simnova.

What industry is Simnova in?

Simnova's product category is Cell Therapy. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YicaiglobalChina’s Simnova Bags USD59.5 Million in New Funding to Advance Off-the-Shelf Cell TherapiesSimnova Biotech raised CNY400 million (USD59.5 million) in a Series B round co-led by Fortera Capital and Pudong Venture Capital. The funds will accelerate confirmatory trials for its lead CAR-NK therapy SNC103 and the In Vivo CAR-T platform SNC116. SNC103 showed positive results in a Phase I trial for lupus and could become the first approved off-the-shelf CAR-NK product.ChinaventureXianbo Biotechnology completed nearly 400 million yuan in Series B financing.Simnova completed nearly 400 million yuan in Series B financing, co-led by Foton Capital, Qianji Capital, and Pudong Venture Capital. The funds will accelerate confirmatory clinical research of the universal CAR-NK core pipeline SNC103 and promote the in vivo CAR-T platform SNC116 into registered clinical development.JixinXianbo Biotechnology completed nearly 400 million yuan in Series B financing.Xianbo Biotechnology completed nearly 400 million yuan in Series B financing, led by Futen Capital, Qianji Capital, and Pudong Venture Capital, with existing shareholders increasing stakes. The funds will accelerate confirmatory clinical research of the universal CAR-NK pipeline SNC103 and promote the in vivo CAR-T platform SNC116 into registered clinical development.PR NewswireSimnova and Orna Therapeutics Collaborate to Advance Orna's Next Generation Circular RNA Technology in ChinaOrna Therapeutics and Simnova announced a collaboration agreement to discover, develop, and commercialize multiple oncology therapeutics in Greater China. Under the terms, Simnova gains access to Orna's isCAR circular RNA technology platform, including the lead ORN-101 anti-CD19 program, while leading clinical development, regulatory submissions, and commercialization in the region; Orna receives an upfront payment plus eligibility for development, regulatory, and sales milestones and royalties. The partnership leverages Orna's engineered circular RNA and proprietary lipid nanoparticle delivery technology, which the company states offers advantages over traditional linear mRNA therapies including greater stability and increased protein expression.